Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.

Bishop C, George JA, Buchta W, Goldenberg AA, Mohamed M, Dickinson SO, Eissa S, Eskow Jaunarajs KL.

Eur J Neurosci. 2012 Sep;36(6):2839-48. doi: 10.1111/j.1460-9568.2012.08202.x. Epub 2012 Jul 5.

2.

Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.

Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell'isola R, Katzman AC, Bishop C.

Neuropharmacology. 2014 Feb;77:1-8. doi: 10.1016/j.neuropharm.2013.09.017. Epub 2013 Sep 22.

3.

Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats.

Conti MM, Goldenberg AA, Kuberka A, Mohamed M, Eissa S, Lindenbach D, Bishop C.

Pharmacol Biochem Behav. 2016 Mar;142:64-71. doi: 10.1016/j.pbb.2016.01.004. Epub 2016 Jan 11.

PMID:
26791104
4.

The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.

Eskow KL, Gupta V, Alam S, Park JY, Bishop C.

Pharmacol Biochem Behav. 2007 Aug-Sep;87(3):306-14. Epub 2007 May 13.

PMID:
17553556
5.

5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.

Tronci E, Lisci C, Stancampiano R, Fidalgo C, Collu M, Devoto P, Carta M.

Neurobiol Dis. 2013 Dec;60:108-14. doi: 10.1016/j.nbd.2013.08.014. Epub 2013 Sep 1.

PMID:
24004632
6.

Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

Fidalgo C, Ko WK, Tronci E, Li Q, Stancampiano R, Chuan Q, Bezard E, Carta M.

Neuroscience. 2015 Jul 9;298:389-96. doi: 10.1016/j.neuroscience.2015.04.027. Epub 2015 Apr 20.

PMID:
25907446
7.

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A.

Exp Neurol. 2015 Sep;271:335-50. doi: 10.1016/j.expneurol.2015.05.021. Epub 2015 May 30.

PMID:
26037043
8.

The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.

McCreary AC, Varney MA, Newman-Tancredi A.

Neuropharmacology. 2016 Jun;105:651-60. doi: 10.1016/j.neuropharm.2016.01.013. Epub 2016 Jan 9.

PMID:
26777281
9.

Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.

Conti MM, Meadows SM, Melikhov-Sosin M, Lindenbach D, Hallmark J, Werner DF, Bishop C.

Neuropharmacology. 2016 Nov;110(Pt A):125-34. doi: 10.1016/j.neuropharm.2016.07.025. Epub 2016 Jul 21.

PMID:
27452719
10.

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

Carta M, Carlsson T, Kirik D, Björklund A.

Brain. 2007 Jul;130(Pt 7):1819-33. Epub 2007 Apr 23.

PMID:
17452372
11.

Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.

Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD.

J Neurosci Res. 2009 May 15;87(7):1645-58. doi: 10.1002/jnr.21978.

12.

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.

Bézard E, Muñoz A, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.

Neurosci Res. 2013 Dec;77(4):242-6. doi: 10.1016/j.neures.2013.10.002. Epub 2013 Oct 14.

PMID:
24135129
13.

Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia.

Meadows SM, Chambers NE, Conti MM, Bossert SC, Tasber C, Sheena E, Varney M, Newman-Tancredi A, Bishop C.

Exp Neurol. 2017 Jun;292:168-178. doi: 10.1016/j.expneurol.2017.03.013. Epub 2017 Mar 23.

PMID:
28342749
14.

Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats.

Cantuti-Castelvetri I, Hernandez LF, Keller-McGandy CE, Kett LR, Landy A, Hollingsworth ZR, Saka E, Crittenden JR, Nillni EA, Young AB, Standaert DG, Graybiel AM.

PLoS One. 2010 Nov 10;5(11):e13861. doi: 10.1371/journal.pone.0013861.

15.

Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.

García J, Carlsson T, Döbrössy M, Nikkhah G, Winkler C.

Neurobiol Dis. 2011 Sep;43(3):576-87. doi: 10.1016/j.nbd.2011.05.004. Epub 2011 May 13.

PMID:
21600983
16.

Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.

Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron GE, Lormand L, Park JY, Bishop C.

Psychopharmacology (Berl). 2008 Jul;199(1):99-108. doi: 10.1007/s00213-008-1135-6. Epub 2008 Jun 11.

PMID:
18545986
17.

Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.

Bhide N, Lindenbach D, Barnum CJ, George JA, Surrena MA, Bishop C.

J Neurochem. 2015 Jul;134(2):222-32. doi: 10.1111/jnc.13125. Epub 2015 Apr 27.

18.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

PMID:
18952677
19.

Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.

Lindenbach D, Palumbo N, Ostock CY, Vilceus N, Conti MM, Bishop C.

Br J Pharmacol. 2015 Jan;172(1):119-30. doi: 10.1111/bph.12894. Epub 2014 Nov 24.

20.

Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.

Neuropharmacology. 2015 Jun;93:52-67. doi: 10.1016/j.neuropharm.2015.01.012. Epub 2015 Jan 31.

PMID:
25645393

Supplemental Content

Support Center